Skip to content

Catalyst Biosciences

Primary Menu

About
Pipeline
Science
- Overview
- Publications
Clinical Trials
- Overview
- CB 4332
- MAA-304
- MAA-202
Investors
Careers
Contact

Investors

Press Releases

Keyword Search

Year

July 22, 2021

Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies

July 19, 2021

Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

July 14, 2021

Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company

July 6, 2021

Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis

July 1, 2021

Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs

June 28, 2021

Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency

June 10, 2021

Catalyst Biosciences to Participate in Two Upcoming Investor Conferences

May 18, 2021

Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra

May 13, 2021

Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit

May 6, 2021

Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update

May 5, 2021

Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors

April 19, 2021

Catalyst Biosciences Announces Publication of CB 2679d Preclinical FIX Gene Therapy Data in Blood, the Journal of the American Society of Hematology

April 12, 2021

Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders

April 7, 2021

Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference

March 4, 2021

Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update

February 18, 2021

Catalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors Conference

February 11, 2021

Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock

February 3, 2021

Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

January 29, 2021

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

January 27, 2021

Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

January 26, 2021

Catalyst Biosciences Announces Proposed Public Offering of Common Stock

January 20, 2021

Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress

January 15, 2021

Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital

Overview
Press Releases
Events and Presentations
Financials & Filings
Stock Information
- Stock Quote
- Stock Chart
Corporate Governance
Investor FAQ

Shareholder Tools

Print Page
RSS Feeds
Email Alerts

About
Pipeline
Science
- Overview
- Publications
Clinical Trials
- Overview
- CB 4332
- MAA-304
- MAA-202
Investors
Careers
Contact

Catalyst Biosciences

Catalyst Biosciences
| 611 Gateway Blvd., Suite 710,
South San Francisco, CA 94080

© Catalyst Biosciences. All rights reserved.
Terms of Use Privacy Policy Cookie Notice

Twitter
LinkedIn
Facebook